

Structural Parallels Between the Cardiotonic Steroids and the *Erythrophleum* Alkaloids - II. Synthesis and Na⁺,K⁺-ATPase Inhibitory Activity of Novel *Erythrophleum* Alkaloid Analogues


Robert W Baker, John R Knox, Brian W Skelton and Alan H White

School of Chemistry, The University of Western Australia, Nedlands, Western Australia, 6009

(Received in UK 3 July 1991)

Abstract *Erythrophleum* alkaloid analogues, which differ in the ester side-chain configuration, in the nature of the 14-axial substituent (H, Me, Et) and in their absolute configuration, have been prepared. A pronounced trend towards increased Na⁺,K⁺-ATPase inhibitory activity occurs through the H, Me and Et series, with the *E* side-chain configuration more active than the *Z*. This trend is largely confined to the analogues with an absolute configuration matching that of the natural alkaloids. A structural parallel between the 14-axial alkyl substituent of the alkaloids and the D-ring of the cardiotonic steroids is proposed.

In Part 1¹ we reported the synthesis of the phenanthrenones (1), (2) and (3) and now describe their conversion to analogues of the *Erythrophleum* alkaloids possessing B- and C-ring functionality present in the natural products, but largely ignored in previous structure-activity studies.




(1) R = H (2) R = Me (3) R = Et


Introduction of the required α,β -unsaturated ester side-chain into the phenanthrenone (1) was accomplished by a Horner-Emmons² reaction with the lithium salt of triethylphosphonoacetate carbanion in tetrahydrofuran for two hours at room temperature. The *E* and *Z* isomers (4) and (5) were formed in a ratio of ca 2:1 respectively, in a total yield of 76%, and could be separated by careful radial chromatography using 15% ethyl acetate/toluene as eluant, in other solvent systems the isomers were co-incident.

Treatment of the methyl-substituted phenanthrenone (2) under the same Horner-Emmons reaction conditions gave the *E*- α,β -unsaturated ester (6) in 43% yield, with only a trace of the *Z* isomer (7) evident by tlc analysis, the ethyl-substituted phenanthrenone (3) failed to react at all.

Since for the purpose of comparison of biological activity we required the *E* and *Z* isomers in both the methyl- and ethyl-substituted series, an alternative olefination procedure was followed. The alcohol group of (2) was protected as its THP ether (using 2,6-dimethylpyridinium *p*-toluenesulphonate as catalyst to avoid epimerisation of the methyl group¹) and the ketone was then treated with ethyl lithio(trimethylsilyl)acetate³. Removal of the THP protecting group (pyridinium *p*-toluenesulphonate/ethanol), followed by radial chromatography, gave *E* and *Z* isomers (6) and (7) in overall yields from (2) of 39% and 21% respectively. In a precisely analogous manner the ethyl-phenanthrenone (3) was transformed, *via* the THP derivative, into the *E* and *Z* isomers (8) and (9) in 21% and 44% yield respectively. The decreased preference for the *E* configuration in the Peterson olefination with ethyl lithio(trimethylsilyl)acetate was anticipated on the basis of work by Battiste *et al*⁴ who found that the stereoselectivity of the Peterson olefination is often complementary to that of the Horner-Emmons reaction.



- (4) $R^1 = H, R^2 = Et$
 (6) $R^1 = Me, R^2 = Et$
 (8) $R^1 = Et, R^2 = Et$
 (10) $R^1 = H, R^2 = CH_2CH_2NMe_2$
 (12) $R^1 = Me, R^2 = CH_2CH_2NMe_2$
 (14) $R^1 = Et, R^2 = CH_2CH_2NMe_2$




- (5) $R^1 = H, R^2 = Et$
 (7) $R^1 = Me, R^2 = Et$
 (9) $R^1 = Et, R^2 = Et$
 (11) $R^1 = H, R^2 = CH_2CH_2NMe_2$
 (13) $R^1 = Me, R^2 = CH_2CH_2NMe_2$
 (15) $R^1 = Et, R^2 = CH_2CH_2NMe_2$

Assignment of the *E* and *Z* configuration to compounds (4) to (9) followed from analysis of the ¹H n m r and ¹³C n m r spectra of the isomers. In the ¹H n m r spectra of the isomers deshielding of the equatorial hydrogen at either C-1 or C-3 by the proximate side-chain carbonyl group of the *Z* and *E* isomers respectively allowed the isomers to be readily differentiated⁵. The shielding of C-1 or C-3 in the ¹³C n m r spectra of the isomers due to the γ -effect⁶ of the side-chain carbonyl group confirmed the stereochemical assignments.

All of the alkyl-substituted products (6), (7), (8) and (9) retained the alkyl group in the axial configuration. This was concluded from the magnitude of the coupling constant between H-1 and H-10a in the ¹H n m r spectra of the respective compounds (4 Hz in each case). Comparison of the ¹³C n m r spectra of (6) and (7) with those of the corresponding des-methyl compounds (4) and (5) revealed a shielding effect at C-3 (4.5 p p m for (6) and 3.0 p p m for (7)), C-4a (6.8 and 7.0 p p m) and C-10 (3.7 and 3.8 p p m), also indicating that the methyl group remained axial in (6) and (7)⁷. Similar observations were made in the ¹³C n m r spectra of the ethyl-substituted products (8) and (9).

The α,β -unsaturated ethyl esters (4) to (9) were converted to the 2-(dimethylamino)ethyl esters (10) to (15) by hydrolysis of the ethyl ester (aqueous sodium hydroxide in dioxane), and then re-esterification with 2-(dimethylamino)ethanol using 2-bromo-1-methylpyridinium iodide as the coupling agent⁸. The overall yields of the alkaloid analogues thus obtained were in the range 69-97%.

In order to unequivocally demonstrate the structural specificity of the interaction of our analogues with the enzyme Na^+, K^+ -ATPase, it was decided to resolve key analogues into their constituent enantiomers.⁹ This has been efficiently carried out by separation of the diastereomers resulting from esterification of the B-ring hydroxyl groups of (4) and (8) with an enantiomerically pure chiral acid. Esterification of (4) with (*R*)-(-)-*O*-methylmandelic acid, using oxalyl chloride/dimethylformamide as the coupling agent,¹⁰ gave the mixture of diastereomers (16) and (17). The mixture was separable by careful radial chromatography on a small scale (*ca* 100 mg) but attempts to scale up the separation failed. Esterification of (4) with (1*S*)-(-)-camphanic acid gave the mixture of (18) and (19), but the diastereomers were again chromatographically inseparable on a preparative scale. It was found, however, that a single fractional crystallisation of the mixture afforded one of the diastereomers in a highly crystalline form, in 36% yield from the racemic alcohol (4). Hplc analysis of the crystalline fraction indicated a 100% diastereomeric excess (d.e.) of the shorter retention time diastereomer. The configuration of this diastereomer (18) was determined by X-ray crystallography (Figure 1) and the absolute configuration of the parent alcohol was thus inferred to be (4*aS*,10*S*,10*aS*).



Hplc analysis of the mother liquor from fractional crystallisation of (18) indicated an 86% d.e. of the longer retention time diastereomer (19). All attempts to induce crystallisation failed. Consequently, the camphanate group of (19) was removed by transesterification with K_2CO_3 in ethanol, and the alcohol group was re-esterified with (*R*)-(-)-*O*-methylmandelic acid. A single fractional crystallisation afforded the (4*aR*,10*R*,10*aR*)-*O*-methylmandelate (17), of 100% d.e. by hplc analysis, in 24% overall yield from the racemate (4).

Optical resolution of the axial 1-ethyl compound (8) proceeded more smoothly than in the case of (4). Esterification of (8) with (*R*)-(-)-*O*-methylmandelic acid, again using oxalyl chloride/dimethylformamide as the coupling agent,¹⁰ gave a mixture of diastereomers (20) and (21), which were readily separable by radial chromatography. The two diastereomers were isolated in 47% and 46% yield respectively, and each was shown to be of 100% d.e. by hplc analysis. The longer retention time isomer (21) was crystalline, and its configuration was determined by X-ray crystallography (Figure 2), again allowing the absolute configuration of the parent alcohol to be inferred as (1*S*,4*aR*,10*R*,10*aR*).

Removal of the camphanate group from (18) and the *O*-methylmandelate groups from (17), (20) and (21) by transesterification with K_2CO_3 /ethanol, afforded the optically active alcohols (+)-(-)-4, (-)-(-)-4, (+)-(-)-8 and (-)-(-)-8 in yields of 71%, 92%, 87% and 80% respectively. The optically active ethyl esters were then converted to

the optically active alkaloid analogues (+)-(10), (-)-(10), (+)-(14) and (-)-(14) using the same procedure described for the preparation of the racemic analogues.




Figure 1 Projection of (18) perpendicular to the fused ring plane, 20% thermal ellipsoids are shown for the non-hydrogen atoms, with carbon numbering Hydrogen atoms have arbitrary radii of 0.1 Å






Figure 2 Projection of (21) perpendicular to the fused ring plane, 20% thermal ellipsoids are shown for the non-hydrogen atoms, with carbon numbering Hydrogen atoms have arbitrary radii of 0.1 Å



- (+)-(4) R¹ = H, R² = Et
 (+)-(8) R¹ = Et, R² = Et
 (+)-(10) R¹ = H, R² = CH₂CH₂NMe₂
 (+)-(14) R¹ = Et, R² = CH₂CH₂NMe₂



- (-)-(4) R¹ = H, R² = Et
 (-)-(8) R¹ = Et, R² = Et
 (-)-(10) R¹ = H, R² = CH₂CH₂NMe₂
 (-)-(14) R¹ = Et, R² = CH₂CH₂NMe₂


A preliminary assessment of the ability of our analogues to inhibit Na⁺,K⁺-ATPase isolated from porcine cerebral cortex is summarised in Table 1. Under the conditions of the assay the IC₅₀ of the *Erythrophleum* alkaloid cassaine (22) was found to be 1.1 μM, which is comparable to the values reported for the inhibition by (22) of Na⁺,K⁺-ATPase isolated from human heart ventricle¹¹ (0.65 μM) and from calf¹² or dog hearts¹³ (each 1 μM).

A comparison of the IC₅₀ of compound (10) with those of the other racemic analogues with the *E* configuration, (12) and (14), revealed that a significant increase in Na⁺,K⁺-ATPase inhibitory activity occurs through introduction of the axial methyl group, and that a further increase takes place through introduction of the axial ethyl group. The same trend, but with reduced magnitude, was observed with the less active *Z* isomers (11), (13) and (15).

The most active of the analogues, the optically pure ethyl-substituted compound (+)-(14) had an inhibitory activity approaching that of the natural alkaloid cassaine (22). The absolute configuration of this compound matches that of the corresponding chiral centres in the B- and C-rings of cassaine (22). The enantiomeric analogue (-)-(14) was much less active. For the optically pure analogues lacking alkyl substitution, (+)-(10) and (-)-(10), there was a less substantial difference in activity between the enantiomers, however, it is again the analogue with an absolute configuration matching that of cassaine (22) that is the more active. The increase in activity observed on introduction of the axial ethyl group into the racemic analogues is seen to be largely confined to the analogues with an absolute configuration matching that of the natural alkaloids.

Table 1. Na⁺,K⁺-ATPase inhibitory activities of the analogues prepared in this study

Compound	IC ₅₀ (μM)
(10)	500
(+)-(10)	200
(-)-(10)	1500
(11)	1400
(12)	25
(13)	200
(14)	8.7
(+)-(14)	3.8
(-)-(14)	930
(15)	50
cassaine (22)	1.1



Previous structure-activity studies on the cardiotonic steroids carried out by Fullerton *et al*¹⁴ demonstrate that the position of the side-chain carbonyl oxygen atom of the steroids plays a crucial role in determining both Na⁺,K⁺-ATPase inhibitory activity and inotropic activity, and suggest that the presence of a *cis*-fused D-ring does not play a significant *direct* role in determining activity. However, Repke *et al.*¹⁵ have proposed that the presence of the *cis*-fused D-ring is important in determining the specificity of action of the cardiotonic steroids. Steroid analogues lacking a *cis*-fused D-ring, although able to inhibit Na⁺,K⁺-ATPase, often do not elicit a positive inotropic effect¹⁶⁻¹⁸. It has been suggested¹⁵ that these analogues are also capable of inhibiting other intracellular metabolic processes (for example digitalis-insensitive mitochondrial Mg²⁺-ATPase¹⁹) which interferes with the development of a positive inotropic effect. In view of the biochemical evidence indicating that the cardiotonic steroids and the *Erythrophleum* alkaloids share the same binding site on Na⁺,K⁺-ATPase,^{13,20} we propose that the supposed sub-site for the D-ring of the cardiotonic steroids also accommodates the axial ethyl group of our analogues, and presumably the 14 α -methyl group of the natural alkaloids.




Figure 3 Superimposition of (+)-(14) with digitoxigenin (23)

We have modelled the structure of (+)-(14)²¹ with the side-chain in an *s-cis,syn* conformation,²⁴ and superimposed it with the X-ray crystal structure of digitoxigenin (23)²⁵ (Figure 3). The predicted minimum energy conformation of the ethyl group in the modelled structure has a C10a-C1-C11-C12 (phenanthrene numbering, where C11 and C12 are the methylene and methyl carbons respectively of the ethyl group) torsion

angle of -167° , close to that observed in the X-ray crystal structure of (21) (-178° for the enantiomer of (21), Figure 2) The preference for this conformation of the ethyl group is supported by the ^1H n.m.r. spectral data of compounds (8), (9), (14) and (15) In each case the coupling constants to H-1 from the ethyl group methylene protons were 4 Hz and 11.5 Hz, suggesting the predominance of a conformation with a C10a-C1-C11-C12 torsion angle of around 180° or -60° ²⁶ However, molecular modelling has indicated that the -60° conformation is significantly disfavoured through an unfavourable steric interaction between the terminal methyl and H-10 The superimposition, carried out by minimising the squared distances between C-5 through to C-16 of digitoxigenin (23) and the corresponding atoms of the B- and C-rings and axial ethyl group of the analogue, illustrates the proposed structural parallel between the axial ethyl group and the D-ring of digitoxigenin (23)

Crystallography

Structure determination Unique data sets were measured at ~ 295 K to the specified $2\theta_{\text{max}}$ limit using an ENRAF-Nonius CAD-4 diffractometer (monochromatic Mo $K\alpha$ radiation source ($\lambda = 0.71073 \text{ \AA}$), $2\theta/\theta$ scan mode) N Independent reflections were obtained, N_{O} with $I > 3\sigma(I)$ being considered 'observed' and used without absorption correction in the full matrix least squares refinements after solution of the structures by direct methods Anisotropic thermal parameters were refined for C, O, (x, y, z, U_{iso})_H were included, constrained at estimated values Conventional residuals R, R_{w} on $|F|$ are quoted at convergence, statistical weights derivative of $\sigma^2(I) = \sigma^2(I_{\text{diff}}) + n_{\text{w}} \times 10^{-4} \sigma^4(I_{\text{diff}})$ were employed Neutral atom complex scattering factors were employed, chirality being assigned on internal chemical grounds, computation used the XTAL 2.6 program system implemented by S R Hall Pertinent results are given in Figures 1 and 2, and Table 2, material deposited with the journal comprises thermal and hydrogen atom parameters, molecular non-hydrogen geometries and structure factor amplitudes

Crystal/refinement data

(18) $\text{C}_{29}\text{H}_{36}\text{O}_7, M_{\text{r}} = 496.6$ Orthorhombic, space group $P2_12_12_1 (D_2^4, \text{No } 19)$, $a = 17.623(2)$, $b = 15.564(2)$, $c = 9.723(1) \text{ \AA}$, $V = 2667 \text{ \AA}^3$ $D_{\text{c}} (Z = 4) = 1.24 \text{ g cm}^{-3}$, $F(000) = 1064$ $\mu_{\text{Mo}} = 0.5 \text{ cm}^{-1}$, specimen $0.42 \times 0.40 \times 0.25 \text{ mm}$ $2\theta_{\text{max}} = 50^\circ$, $N = 2658$, $N_{\text{O}} = 1880$, $R = 0.045$, $R_{\text{w}} = 0.049$ ($n_{\text{w}} = 7$)

(21) $\text{C}_{30}\text{H}_{36}\text{O}_6, M_{\text{r}} = 492.6$ Orthorhombic, space group $P2_12_12_1$, $a = 5.180(3)$, $b = 17.016(7)$, $c = 31.37(1) \text{ \AA}$, $V = 2765 \text{ \AA}^3$ $D_{\text{c}} (Z = 4) = 1.18 \text{ g cm}^{-3}$, $F(000) = 1056$ $\mu_{\text{Mo}} = 0.5 \text{ cm}^{-1}$, specimen $0.45 \times 0.28 \times 0.22 \text{ mm}$ $2\theta_{\text{max}} = 45^\circ$, $N = 1799$, $N_{\text{O}} = 1264$; $R = 0.082$, $R_{\text{w}} = 0.098$ ($n_{\text{w}} = 4$)

Abnormal features/variation in procedure Nicely formed crystals of (21) nevertheless gave unusually wide line widths which, in conjunction with the long cell axis, caused resolution difficulties, resolved by the use of an ω -scan data collection mode with appropriate slit width Thermal motion in the structure is exceedingly high, particularly in the pendant substituents and is considered the chief contributing factor to the high residual

Table 2. Non-hydrogen atom co-ordinates

Atom	(18)			Atom	(21)		
	x	y	z		x	y	z
C(1)	0 7264(2)	0 2093(2)	0 0623(4)	C(11)	1 020(2)	0 4877(7)	0 1698(4)
C(2)	0 6823(2)	0 1981(2)	-0 0693(4)	C(12)	1 052(3)	0 4046(7)	0 1832(3)
C(21)	0 6582(2)	0 2660(2)	-0 1389(4)	C(1)	0 776(2)	0 5065(5)	0 1431(3)
C(22)	0 6136(2)	0 2649(2)	-0 2675(4)	C(2)	0 744(2)	0 4577(5)	0 1052(3)
O(22)	0 5823(2)	0 2051(2)	-0 3192(3)	C(21)	0 589(2)	0 3983(6)	0 1046(3)
O(23)	0 6104(2)	0 3437(2)	-0 3189(3)	C(22)	0 528(3)	0 3423(7)	0 0689(4)
C(23)	0 5681(3)	0 3545(3)	-0 4477(6)	O(22)	0 597(2)	0 3435(5)	0 0338(2)
C(24)	0 5504(3)	0 4440(4)	-0 4629(6)	O(23)	0 347(2)	0 2867(4)	0 0834(2)
C(3)	0 6682(2)	0 1064(2)	-0 1082(4)	C(23)	0 268(3)	0 2299(7)	0 0545(4)
C(4)	0 6338(2)	0 0560(2)	0 0103(4)	C(24)	0 129(4)	0 1728(8)	0 0769(4)
C(4a)	0 6802(2)	0 0639(2)	0 1421(4)	C(3)	0 911(2)	0 4764(6)	0 0688(3)
C(4b)	0 6497(2)	0 0103(2)	0 2597(4)	C(4)	0 880(2)	0 5616(7)	0 0567(3)
C(5)	0 6211(2)	-0 0712(2)	0 2381(4)	C(4a)	0 922(2)	0 6170(7)	0 0948(3)
C(6)	0 5948(2)	-0 1220(2)	0 3434(5)	C(4b)	0 894(2)	0 7071(6)	0 0842(4)
C(7)	0 5968(2)	-0 0915(3)	0 4771(4)	C(5)	1 035(3)	0 7306(7)	0 0471(4)
O(7)	0 5738(2)	-0 1362(2)	0 5906(3)	C(6)	1 009(3)	0 8095(9)	0 0376(5)
C(71)	0 5487(3)	-0 2223(3)	0 5730(7)	C(7)	0 829(3)	0 8606(7)	0 0609(4)
C(8)	0 6259(2)	-0 0102(2)	0 5008(4)	O(7)	0 819(2)	0 9364(5)	0 0418(3)
C(8a)	0 6535(2)	0 0400(2)	0 3949(4)	C(71)	0 645(4)	0 9868(8)	0 0589(5)
C(9)	0 6884(2)	0 1264(2)	0 4300(4)	C(8)	0 719(3)	0 8332(7)	0 0956(4)
C(10)	0 7352(2)	0 1622(2)	0 3137(4)	C(8a)	0 749(2)	0 7557(6)	0 1079(4)
O(10)	0 7542(1)	0 2512(1)	0 3446(3)	C(9)	0 636(2)	0 7284(6)	0 1490(3)
C(101)	0 8182(2)	0 2647(2)	0 4125(4)	C(10)	0 741(2)	0 6526(6)	0 1647(3)
O(101)	0 8612(2)	0 2085(2)	0 4475(4)	O(10)	0 596(2)	0 6251(4)	0 2008(2)
C(102)	0 8356(2)	0 3567(2)	0 4384(4)	C(101)	0 666(2)	0 6571(7)	0 2399(3)
O(102)	0 7661(1)	0 4085(1)	0 4333(3)	O(101)	0 833(2)	0 6999(5)	0 2450(2)
C(103)	0 8897(2)	0 3982(3)	0 3358(4)	C(102)	0 491(3)	0 6190(7)	0 2754(3)
C(104)	0 9088(2)	0 4837(2)	0 4094(4)	O(102)	0 511(2)	0 6675(6)	0 3107(3)
C(105)	0 8635(2)	0 4787(2)	0 5463(4)	C(1021)	0 352(4)	0 7220(8)	0 3137(5)
C(106)	0 7823(2)	0 4838(2)	0 4983(4)	C(103)	0 603(2)	0 5389(8)	0 2858(3)
O(106)	0 7369(2)	0 5404(2)	0 5083(3)	C(104)	0 510(4)	0 4696(9)	0 2686(4)
C(107)	0 8684(2)	0 3815(2)	0 5805(4)	C(105)	0 602(5)	0 3953(9)	0 2806(5)
C(1051)	0 8849(3)	0 5435(3)	0 6554(5)	C(106)	0 804(3)	0 396(1)	0 3068(5)
C(1071)	0 9489(2)	0 3493(3)	0 6084(4)	C(107)	0 886(3)	0 467(1)	0 3287(5)
C(1072)	0 8172(3)	0 3550(3)	0 6996(4)	C(108)	0 791(3)	0 5304(9)	0 3167(5)
C(10a)	0 6896(2)	0 1590(2)	0 1801(4)	C(10a)	0 735(2)	0 5919(6)	0 1303(3)

Experimental

General General directions are given in Part 1.¹

Materials (1*S*)-(-)-Camphanic acid was prepared in three steps from natural (+)-camphor. (+)-Camphor was oxidised to camphoric acid with nitric acid according to the procedure of Bredt²⁷ This was then converted to α -bromocamphoric anhydride according to the procedure of Meyer *et al*²⁸ Finally, treatment of α -bromocamphoric anhydride with potassium acetate in glacial acetic acid, according to the procedure of Lapworth and Lenton,²⁹ gave (1*S*)-(-)-camphanic acid. Racemic *O*-methylmandelic acid was resolved *via* the (-)-ephedrine salts according to the procedure of Neilson and Peters³⁰ The optical purity of the resolved (*R*)-(-)-*O*-methylmandelic acid was assessed by ¹H n.m.r. spectroscopy at 80 MHz. Addition of *ca.* 5 mol% of tris[3-(heptafluoropropyl)hydroxymethylene]-*d*-camphorato] europium (III) to a 10% CDCl₃ solution of the methylated (diazomethane) (-)-acid established, by comparison with the spectrum obtained with the methylated racemic acid (which displayed two well resolved signals for the C-2 methine proton), that the enantiomeric excess was greater than 99%

Ethyl (E)-(4*aR**,10*R**,10*aR**)-10-Hydroxy-7-methoxy-3,4,4*a*,9,10,10*a*-hexahydrophenanthren-2(1*H*)-ylideneacetate (4) and *Ethyl* (Z)-(4*aR**,10*R**,10*aR**)-10-Hydroxy-7-methoxy-3,4,4*a*,9,10,10*a*-hexahydrophenanthren-2(1*H*)-ylideneacetate (5) A solution of *n*-BuLi (18.4 ml, 1.63 M in hexane, 30 mmol) was added dropwise to a stirred solution of triethyl phosphonoacetate (5.9 ml, 30 mmol) in THF (100 ml) at 0° under an atmosphere of

Ar On warming to room temperature the ketone (1)¹ (5.00 g, 20 mmol) was added and the mixture was stirred for 2 hours. The reaction mixture was then diluted with CH₂Cl₂, washed with water, dried (MgSO₄) and the solvent was removed *in vacuo*. The products were separated by radial chromatography (15% EtOAc/toluene), the (*E*) ester (4) being eluted first, followed by the (*Z*) ester (5). The (*E*) ester (4) (3.14 g, 49%) crystallised from CH₂Cl₂/petrol, m.p. 127-8°. Found: C, 72.33, H, 7.76%. C₁₉H₂₄O₄ requires C, 72.13, H, 7.65%, ¹H n.m.r. (300 MHz, CDCl₃): δ 1.28 (t, *J* 7 Hz, 3H, OCH₂CH₃), 1.37 (dddd, *J* 3.5, 13, 13, 13 Hz, 1H, H-4_{ax}), 1.53 (dddd, *J* 3.5, 10, 12, 12 Hz, 1H, H-10a), 1.97-2.09 (m, 2H, H-1_{ax}, H-3_{ax}), 2.52-2.64 (m, 2H, H-4_{eq}, H-4a), 2.80 (dd, *J* 10, 16 Hz, 1H, H-9_{ax}), 2.85 (ddd, *J* 2, 3.5, 12 Hz, 1H, H-1_{eq}), 3.14 (dd, *J* 6, 16 Hz, 1H, H-9_{eq}), 3.78 (s, 3H, OMe), 3.80 (m, W_{h/2} 30 Hz, 1H, H-10), 4.06 (dm, *J* 14 Hz/W_{h/2} 8 Hz, 1H, H-3_{eq}), 4.15 (q, *J* 7 Hz, 2H, OCH₂CH₃), 5.73 (s, 1H, vinyl-H), 6.62 (d, *J* 2.5 Hz, 1H, H-8), 6.74 (dd, *J* 2.5, 8.5 Hz, 1H, H-6), 7.19 (d, *J* 8.5 Hz, 1H, H-5), ¹³C n.m.r. (75.5 MHz, CDCl₃) See Table 1, *m/z* 316 (65%, M⁺), 298 (37), 269 (66), 252 (22), 225 (48), 224 (24), 223 (24), 211 (34), 210 (91), 209 (46), 188 (38), 185 (64), 175 (99), 172 (20), 171 (100), 159 (38), 135 (20), 91 (20).

The (*Z*) ester (5) (1.75 g, 27%) crystallised from ether/petrol, m.p. 53-4°. Found: C, 71.96, H, 7.81%. C₁₉H₂₄O₄ requires C, 72.13, H, 7.65%, ¹H n.m.r. (300 MHz, CDCl₃): δ 1.27 (t, *J* 7 Hz, 3H, OCH₂CH₃), 1.41 (dddd, *J* 4, 13, 13, 13 Hz, 1H, H-4_{ax}), 1.49 (dddd, *J* 3, 10, 12, 12 Hz, 1H, H-10a), 1.71 (dd, *J* 12, 12 Hz, 1H, H-1_{ax}), 2.30-2.65 (m, 4H, H-3_{eq}, H-3_{ax}, H-4_{eq}, H-4a), 2.80 (dd, *J* 10, 16 Hz, 1H, H-9_{ax}), 3.17 (dd, *J* 6, 16 Hz, 1H, H-9_{eq}), 3.78 (s, 3H, OMe), 3.83 (ddd, *J* 6, 10, 10 Hz, 1H, H-10), 4.15 (q, *J* 7 Hz, 2H, OCH₂CH₃), 4.41 (ddd, *J* 2, 3, 12 Hz, 1H, H-1_{eq}), 5.71 (s, 1H, vinyl-H), 6.63 (d, *J* 2.5 Hz, 1H, H-8), 6.73 (dd, *J* 2.5, 8.5 Hz, 1H, H-6), 7.16 (d, *J* 8.5 Hz, 1H, H-5), ¹³C n.m.r. (75.5 MHz, CDCl₃) See Table 1, *m/z* 316 (47%, M⁺), 298 (29), 269 (64), 252 (27), 225 (30), 211 (29), 210 (79), 209 (39), 185 (62), 175 (46), 171 (100).

2-(Dimethylamino)ethyl (*E*)-(4aR*,10R*,10aR*)-10-Hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-ylideneacetate (10) A mixture of the ethyl ester (4) (500 mg, 1.6 mmol), dioxane (20 ml) and aqueous sodium hydroxide solution (20 ml, 1M) was stirred at 80° under an atmosphere of Ar for 1 hr. The reaction mixture was then poured into water, acidified with concentrated HCl and extracted with EtOAc. The extract was washed with water, sat. NaCl, dried (MgSO₄) and the solvent was removed *in vacuo*. To a solution of the resulting crude acid in CH₂Cl₂ (15 ml) was added triethylamine (560 μl, 4.0 mmol), dimethylaminoethanol (200 μl, 2.0 mmol) and 2-bromo-1-methylpyridinium iodide⁸ (600 mg, 2.0 mmol) and the mixture was stirred at room temperature under an atmosphere of Ar for 20 hrs. The reaction mixture was diluted with CH₂Cl₂, and was washed with dilute aqueous NH₃ solution, water, dried (MgSO₄) and the solvent was removed *in vacuo*. Radial chromatography (10% MeOH/CHCl₃) gave the ester (10) (450 mg, 79% over two steps) as a solid, m.p. 106-8°. Found: C, 70.09, H, 8.06, N, 3.86%. C₂₁H₂₉NO₄ requires C, 70.17; H, 8.13, N, 3.90%, ¹H n.m.r. (300 MHz, CDCl₃): δ 1.37 (dddd, *J* 3.5, 13, 13, 13 Hz, 1H, H-4_{ax}), 1.53 (dddd, *J* 3.5, 10, 12, 12 Hz, 1H, H-10a), 1.97-2.10 (m, 2H, H-1_{ax}, H-3_{ax}), 2.29 (s, 6H, NMe₂), 2.51-2.65 (m, 4H, H-4_{eq}, H-4a, OCH₂CH₂N), 2.80 (dd, *J* 10, 16 Hz, 1H, H-9_{ax}), 2.85 (dm, *J* 12 Hz/W_{h/2} 6 Hz, 1H, H-1_{eq}), 3.15 (dd, *J* 6, 16 Hz, 1H, H-9_{eq}), 3.78 (s, 3H, OMe), 3.80 (ddd, *J* 6, 10, 10 Hz, 1H, H-10), 4.07 (dm, *J* 14 Hz/W_{h/2} 8 Hz, 1H, H-3_{eq}), 4.20 (t, *J* 6 Hz, 2H, OCH₂CH₂N), 5.78 (s, 1H, vinyl-H), 6.62 (d, *J* 2.5 Hz, 1H, H-8), 6.74 (dd, *J* 2.5, 8.5 Hz, 1H, H-6), 7.19 (d, *J* 8.5 Hz, 1H, H-5), ¹³C n.m.r. (75.5 MHz, CDCl₃) See Table 2, *m/z* 209 (3), 175 (1), 171 (2), 159 (1), 145 (1), 135 (1), 91 (1), 72 (12), 71 (100), 59 (3), 58 (91).

2-(Dimethylamino)ethyl (*Z*)-(4aR*,10R*,10aR*)-10-Hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-ylideneacetate (11) The (*Z*) ethyl ester (5) (500 mg, 1.6 mmol) was converted to the dimethylaminoethyl ester by a method similar to that described for the preparation of the (*E*) analogue (10). The ester (11) (390 mg, 69% over two steps) crystallised from CH₂Cl₂/petrol, m.p. 120-2°. Found: C, 70.24, H, 8.20, N, 3.92%. C₂₁H₂₉NO₄ requires C, 70.17, H, 8.13, N, 3.90%, ¹H n.m.r. (300 MHz, CDCl₃): δ 1.41 (dddd, *J* 4, 13, 13, 13 Hz, 1H, H-4_{ax}), 1.49 (dddd, *J* 3, 10, 12, 12 Hz, 1H, H-10a), 1.71 (dd, *J* 12, 12 Hz, 1H, H-1_{ax}), 2.28 (s, 6H, NMe₂), 2.25-2.67 (m, 6H, H-3_{eq}, H-3_{ax}, H-4_{eq}, H-4a, OCH₂CH₂N), 2.77 (dd, *J* 10, 16 Hz, 1H, H-9_{ax}), 3.18 (dd, *J* 6, 16 Hz, 1H, H-9_{eq}), 3.78 (s, 3H, OMe), 3.80 (ddd, *J* 6, 10, 10 Hz, 1H, H-10), 4.14 (q, *J* 7 Hz, 2H, OCH₂CH₂N), 5.73 (s, 1H, vinyl-H), 6.63 (d, *J* 2.5 Hz, 1H, H-8), 6.73 (dd, *J* 2.5, 8.5 Hz, 1H, H-6), 7.16 (d, *J* 8.5 Hz, 1H, H-5), ¹³C n.m.r. (75.5 MHz, CDCl₃) See Table 2, *m/z* 209 (3), 175 (1), 171 (2), 159 (1), 145 (1), 135 (1), 91 (1), 72 (12), 71 (100), 59 (3), 58 (91).

th water, dried (Na₂SO₄) and the solvent was removed *in vacuo* to give the THP ether derivative as a pale low semi-solid.


To a stirred solution of lithium diisopropylamide, prepared from diisopropylamine (2.2 ml, 16 mmol) and BuLi (8.1 ml, 1.88M in hexane, 15 mmol), in THF (50 ml) at -78° under an atmosphere of Ar, was added dropwise ethyl (trimethylsilyl)acetate (2.8 ml, 15 mmol). The mixture was stirred at -78° for 0.5 hrs, then a solution of the above THP ether derivative in THF (30 ml) was added dropwise. After stirring for 1 hr the reaction mixture was allowed to warm to room temperature over 1 hr, and was then poured into 10% aqueous FeCl₃ solution and extracted with CH₂Cl₂. The extract was washed with dilute HCl, water, dried (MgSO₄) and the solvent was removed *in vacuo*. The residue was dissolved in ethanol (60 ml) with pyridinium *p*-uenesulphonate (300 mg, 1.2 mmol) and the mixture was stirred at 65-70° (bath), under an atmosphere of Ar, for 4 hrs. The solution was cooled, poured into water and extracted with CH₂Cl₂. The extract was washed with water, dried (MgSO₄) and the solvent was removed *in vacuo*. The products were separated by radial chromatography (15% EtOAc/toluene), the (*E*) ester (6) being eluted first, followed by the (*Z*) ester (7). The (*E*) ester (6) (1.64 g, 39% over three steps) crystallised from CH₂Cl₂/petrol, m.p. 75-7°, Found. C, 72.72, H, 8.07%. C₂₀H₂₆O₄ requires C, 72.70, H, 7.93%; ¹H n.m.r. (300 MHz, CDCl₃). δ 1.17 (d, *J* 7 Hz, 3H, Me-1), 1.22-1.37 (m, 4H, H-4_{ax}, OCH₂CH₃), 1.65 (ddd, *J* 4, 11, 11 Hz, 1H, H-10a), 2.22 (dddd, *J* 1.5, 5, 13, 13 Hz, 1H, H-3_{ax}), 2.54 (m, W_{h/2} 24 Hz, 1H, H-4_{eq}), 2.78 (dd, *J* 10, 16 Hz, 1H, H-9_{ax}), 2.88 (br dd, *J*=11, 11 Hz, 1H, H-4a), 2.97 (dq, *J* 4, 7 Hz, 1H, H-1), 3.10 (dd, *J* 5.5, 16 Hz, 1H, H-9_{eq}), 3.76 (s, 3H, OMe), 3.85-3.98 (m, 2H, H-3_{eq}, H-10), 4.15 (q, *J* 7 Hz, 2H, OCH₂CH₃), 5.77 (d, *J* 1.5 Hz, 1H, vinyl-H), 6.59 (d, *J* 5 Hz, 1H, H-8), 6.73 (dd, *J* 2.5, 8.5 Hz, 1H, H-6), 7.18 (d, *J* 8.5 Hz, 1H, H-5); ¹³C n.m.r. (75.5 MHz, CDCl₃). See Table 1, *m/z* 330 (45%, M⁺), 312 (19), 285 (16), 283 (54), 266 (28), 239 (36), 238 (17), 225 (9), 224 (36), 223 (28), 209 (24), 199 (21), 188 (21), 172 (19), 171 (100), 166 (20), 161 (16), 160 (15), 159 (3), 147 (25), 146 (18), 145 (16), 135 (21).

The (*Z*) ester (7) (0.88 g, 21% over three steps) was obtained as a gum, Found. C, 72.72, H, 8.07%. C₂₀H₂₆O₄ requires C, 72.70, H, 7.93%; ¹H n.m.r. (300 MHz, CDCl₃). δ 1.18 (d, *J* 7 Hz, 3H, Me-2), 1.28 (t, *J* 7 Hz, 3H, OCH₂CH₃), 1.35 (m, W_{h/2} 40 Hz, 1H, H-4_{ax}), 1.60 (ddd, *J* 4, 10, 11 Hz, 1H, H-10a), 2.25 (dm, *J* 13 Hz/W_{h/2} 7 Hz, 1H, H-3_{eq}), 2.50-2.69 (m, 2H, H-3_{ax}, H-4_{eq}), 2.80 (dd, *J* 10, 16 Hz, 1H, H-9_{ax}), 2.89 (br dd, *J*=11, 11 Hz, 1H, H-4a), 3.13 (dd, *J* 5, 16 Hz, 1H, H-9_{eq}), 3.77 (s, 3H, OMe), 3.97 (ddd, *J* 5, 10, 10 Hz, 1H, H-10), 4.14 (q, *J* 7 Hz, 2H, OCH₂CH₃), 4.52 (dq, *J* 4, 7 Hz, 1H, H-1), 5.64 (d, *J* 1.5 Hz, 1H, vinyl-H), 5.1 (d, *J* 2.5 Hz, 1H, H-8), 6.75 (dd, *J* 2.5, 8.5 Hz, 1H, H-6), 7.18 (d, *J* 8.5 Hz, 1H, H-5); ¹³C n.m.r. (75.5 MHz, CDCl₃). See Table 1, *m/z* 330 (41%, M⁺), 312 (28), 283 (50), 237 (20), 225 (21), 224 (49), 223 (4), 209 (29), 199 (32), 176 (27), 175 (45), 172 (22), 171 (100), 165 (34), 159 (24), 145 (23).

(Dimethylamino)ethyl (E)-(1R,4aS*,10S*,10aS*)-10-Hydroxy-7-methoxy-1-methyl-3,4,4a,9,10,10a-hexadropheanthren-2(1H)-ylideneacetate (12)* The (*E*) ethyl ester (6) (500 mg, 1.52 mmol) was converted to the dimethylaminoethyl ester by a method similar to that described for the preparation of the (*E*) analogue (10). Purification by radial chromatography (10% MeOH/CHCl₃) gave the ester (12) (454 mg, 80% over two steps) as a gum, Found. C, 70.97, H, 8.29, N, 3.78%. C₂₂H₃₁NO₄ requires C, 70.75, H, 8.37, N, 3.75%; ¹H n.m.r. (300 MHz, CDCl₃). δ 1.17 (d, *J* 7 Hz, 3H, Me-1), 1.28 (dddd, *J* 4, 13, 13, 13 Hz, 1H, H-4_{ax}), 1.65 (ddd, *J* 4, 11 Hz, 1H, H-10a), 2.22 (dddd, *J* 1.5, 5, 13, 13 Hz, 1H, H-3_{ax}), 2.30 (s, 6H, NMe₂), 2.50-2.63 (m, 3H, H-4_{eq}, OCH₂CH₂N), 2.78 (dd, *J* 10, 16 Hz, 1H, H-9_{ax}), 2.88 (br dd, *J*=11, 11 Hz, 1H, H-4a), 2.97 (dq, *J* 4, 7 Hz, 1H, H-1), 3.10 (dd, *J* 5.5, 16 Hz, 1H, H-9_{eq}), 3.76 (s, 3H, OMe), 3.85-3.98 (m, 2H, H-3_{eq}, H-10), 4.13-4.27 (m, 2H, OCH₂CH₂N), 5.82 (d, *J* 1.5 Hz, 1H, vinyl-H), 6.59 (d, *J* 2.5 Hz, 1H, H-8), 6.73 (dd, *J* 2.5, 8.5 Hz, 1H, H-6), 7.18 (d, *J* 8.5 Hz, 1H, H-5); ¹³C n.m.r. (75.5 MHz, CDCl₃). See Table 2, *m/z* 223 (1), 175 (1), 171 (2), 159 (1), 135 (1), 72 (9), 71 (77), 59 (3), 58 (100).

(Dimethylamino)ethyl (Z)-(1R,4aS*,10S*,10aS*)-10-Hydroxy-7-methoxy-1-methyl-3,4,4a,9,10,10a-hexadropheanthren-2(1H)-ylideneacetate (13)* The (*Z*) ethyl ester (7) (670 mg, 2.03 mmol) was converted to the dimethylaminoethyl ester by a method similar to that described for the preparation of the (*E*) analogue (10). Purification by radial chromatography (10% MeOH/CHCl₃) gave the ester (13) (504 mg, 67% over two steps) as a solid, m.p. 120-1°, Found. C, 70.61, H, 8.22, N, 3.61%. C₂₂H₃₁NO₄ requires C, 70.75, H, 8.37, N, 3.75%; ¹H n.m.r. (300 MHz, CDCl₃). δ 1.16 (d, *J* 7 Hz, 3H, Me-2), 1.35 (m, W_{h/2} 40 Hz, 1H, H-4_{ax}), 1.60 (ddd, *J* 4, 10, 11 Hz, 1H, H-10a), 2.25 (dm, *J* 13 Hz/W_{h/2} 7 Hz, 1H, H-3_{eq}), 2.29 (s, 6H, NMe₂), 2.50-2.69 (m, 2H, H-3_{ax}, H-4_{eq}, OCH₂CH₂N), 2.77 (dd, *J* 10, 16 Hz, 1H, H-9_{ax}), 2.89 (br dd, *J*=11, 11 Hz, 1H, H-4a), 3.13 (dd, *J* 5, 16 Hz, 1H, H-9_{eq}), 3.77 (s, 3H, OMe), 3.92 (ddd, *J* 5, 10, 10 Hz, 1H, H-10), 4.13-4.27 (m, 2H, OCH₂CH₂N), 4.47 (dq, *J* 4, 7 Hz, 1H, H-1), 5.66 (d, *J* 1.5 Hz, 1H, vinyl-H), 6.60 (d, *J* 2.5 Hz, 1H, H-8), 6.73 (dd, *J* 2.5, 8.5 Hz, 1H, H-6), 7.17 (d, *J* 8.5 Hz, 1H, H-5); ¹³C n.m.r. (75.5 MHz, CDCl₃). See Table 2, *m/z* 223 (1), 171 (2), 163 (1), 159 (1), 135 (1), 121 (1), 72 (13), 71 (90), 59 (4), 58 (100).


Table 2



Et

(12)	(13)	(14)	(15)
39.6	30.6	47.3	37.5
166.5	165.7	164.3	163.9
24.4	33.3	24.5	33.8
32.6	32.6	32.8	32.6
34.8	34.7	35.6	35.3
130.8	130.7	130.9	130.9
127.1	126.9	127.0	126.8
112.4	112.4	112.4	112.3
157.8	157.7	157.7	157.7
113.4	113.4	113.5	113.5
135.4	135.9	135.4	135.9
40.4	40.3	40.6	40.6
67.4	67.4	67.3	67.4
50.8	50.4	51.8	51.4
55.2	55.2	55.2	55.1
113.6	113.5	114.9	115.3
166.9	166.4	166.5	166.6
13.4	12.4	-	-
-	-	12.0	11.4
-	-	18.6	18.8
57.7	57.8	57.7	57.8
61.2	61.0	61.3	60.9
45.6	45.6	45.6	45.4

Table 1



R = H, Me, Et

Carbon	(4)	(5)	(6)	(7)	(8)	(9)
1	39.5	31.5	39.6	30.3	47.3	37.0
2	160.5	160.4	165.8	165.6	163.4	163.8
3	28.9	37.1	24.4	33.2	24.5	33.6
4	31.5	32.3	32.6	32.7	32.9	32.8
4a	41.6	41.8	34.8	34.8	35.6	35.3
4b	130.5	130.6	130.8	130.8	131.0	130.9
5	126.5	126.2	127.1	126.9	127.1	126.8
6	112.3	112.4	112.4	112.5	112.5	112.4
7	157.8	158.0	157.8	157.8	157.8	157.7
8	113.7	113.8	113.6	113.5	113.6	113.5
8a	135.7	136.2	135.3	135.8	135.3	135.8
9	39.9	39.8	40.4	40.2	40.6	40.4
10	71.3	71.4	67.6	67.6	67.5	67.5
10a	49.1	48.7	50.8	50.2	51.8	51.2
OMe	55.2	55.3	55.2	55.2	55.2	55.2
CHCO ₂	114.4	114.3	113.6	113.5	115.2	115.5
CO ₂	166.8	166.7	167.0	166.4	166.7	166.6
Me-1	-	-	13.5	12.5	-	-
CH ₂ CH ₃	-	-	-	-	12.1	11.3
CH ₂ CH ₃	-	-	-	-	18.7	19.0
OCH ₂ CH ₃	14.3	14.3	14.3	14.3	14.3	14.2
OCH ₂ CH ₃	59.7	59.7	59.6	59.6	59.6	59.6

Ethyl (E)-(1R,4aS*,10S*,10aS*)-1-Ethyl-10-hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-ylideneacetate (8) and Ethyl (Z)-(1R*,4aS*,10S*,10aS*)-1-Ethyl-10-Hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-ylideneacetate (9)*. The ketone (3)¹ (4.6 g, 16.8 mmol) was converted to the *E* and *Z* esters, (8) and (9), according to the procedure described for the preparation of (6) and (7). The products were separated by radial chromatography (15% EtOAc/toluene), the *E* ester (8) being eluted first, followed by the *Z* ester (9). The *E* ester (8) (1.23 g, 21% over three steps) crystallised from CH₂Cl₂/petrol, m p 125-125.5°, Found. C, 73.21, H, 7.96% C₂₁H₂₈O₄ requires C, 73.23, H, 8.19%; ¹H n.m.r. (300 MHz, CDCl₃) δ 0.86 (dd, *J* 7.5, 7.5 Hz, 3H, C(H)HCH₃), 1.29 (t, *J* 7 Hz, 3H, OCH₂CH₃), 1.33 (dddd, *J* 3.5, 13, 13, 13 Hz, 1H, H-4_{ax}), 1.57 (ddq, *J* 11.5, 13, 7.5 Hz, 1H, C(H)HCH₃), 1.62-1.77 (m, 2H, H-10a, C(H)HCH₃), 2.10 (dddd, *J* 1.5, 5, 13, 13 Hz, 1H, H-3_{ax}), 2.55 (m, *W*_{h/2} 24 Hz, 1H, H-4_{eq}), 2.64 (ddd, *J* 4, 4, 11.5 Hz, 1H, H-1), 2.79 (dd, *J* 10, 16 Hz, 1H, H-9_{ax}), 2.90 (ddd, *J* 3, 11, 13 Hz, 1H, H-4a), 3.10 (dd, *J* 5, 16 Hz, 1H, H-9_{eq}), 3.77 (s, 3H, OMe), 3.95 (dm, *J* 13 Hz, *W*_{h/2} 8 Hz, 1H, H-3_{eq}), 4.02 (ddd, *J* 5, 10, 10 Hz, 1H, H-10), 4.16 (q, *J* 7 Hz, 2H, OCH₂CH₃), 5.73 (d, *J* 1.5 Hz, 1H, vinyl-H), 6.60 (d, *J* 2.5 Hz, 1H, H-8), 6.74 (dd, *J* 2.5, 8.5 Hz, 1H, H-6), 7.19 (d, *J* 8.5 Hz, 1H, H-5), ¹³C n.m.r. (75.5 MHz, CDCl₃) See Table 1, *m/z* 344 (35%, M⁺), 326 (16), 299 (16), 297 (61), 280 (23), 253 (35), 223 (33), 209 (29), 190 (16), 188 (27), 180 (28), 175 (61), 172 (28), 171 (100), 163 (19), 161 (17), 160 (15), 159 (25), 147 (24), 146 (21), 135 (23).

The *Z* ester (9) (2.55 g, 44% over three steps) was obtained as a gum; Found. C, 72.97, H, 8.20% C₂₁H₂₈O₄ requires C, 73.23, H, 8.19%, ¹H n.m.r. (300 MHz, CDCl₃) δ 0.87 (dd, *J* 7.5, 7.5 Hz, 3H, C(H)HCH₃), 1.27 (t, *J* 7 Hz, 3H, OCH₂CH₃), 1.36 (m, *W*_{h/2} 45 Hz, 1H, H-4_{ax}), 1.55 (ddq, *J* 11.5, 13, 7.5 Hz, 1H, C(H)HCH₃), 1.64 (ddd, *J* 4, 10, 11 Hz, 1H, H-10a), 1.76 (ddq, *J* 4, 13, 7.5 Hz, C(H)HCH₃), 2.22 (m, *W*_{h/2} 20 Hz, 1H, H-3_{eq}), 2.47-2.61 (m, 2H, H-3_{ax}, H-4_{eq}), 2.78 (dd, *J* 10, 16 Hz, 1H, H-9_{ax}), 2.91 (br dd, *J*=11, 11 Hz, 1H, H-4a), 3.12 (dd, *J* 5, 16 Hz, 1H, H-9_{eq}), 3.77 (s, 3H, OMe), 4.00 (ddd, *J* 5, 10, 10 Hz, 1H, H-10), 4.13 (q, *J* 7 Hz, 2H, OCH₂CH₃), 4.43 (ddd, *J* 4, 4, 11.5 Hz, 1H, H-1), 5.77 (d, *J* 1 Hz, 1H, vinyl-H), 6.60 (d, *J* 2.5 Hz, 1H, H-8), 6.73 (dd, *J* 2.5, 8.5 Hz, 1H, H-6), 7.16 (d, *J* 8.5 Hz, 1H, H-5), ¹³C n.m.r. (75.5 MHz, CDCl₃) See Table 1, *m/z* 344 (30%, M⁺), 326 (23), 299 (18), 298 (16), 297 (62), 253 (27), 251 (17), 239 (15), 238 (19), 223 (41), 213 (38), 209 (34), 190 (18), 188 (30), 179 (35), 175 (50), 172 (30), 171 (100), 159 (24), 146 (16), 135 (20).

2-(Dimethylamino)ethyl (E)-(1R,4aS*,10S*,10aS*)-1-Ethyl-10-hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-ylideneacetate (14)*. The *E* ethyl ester (8) (350 mg, 1.02 mmol) was converted to the dimethylaminoethyl ester by a method similar to that described for the preparation of the *E* analogue (10). Purification by radial chromatography (10% MeOH/CHCl₃) gave the ester (14) (380 mg, 97% over two steps) as a gum, Found. C, 71.50; H, 8.52, N, 3.67% C₂₃H₃₃NO₄ requires C, 71.29; H, 8.58; N, 3.61%, ¹H n.m.r. (300 MHz, CDCl₃) δ 0.83 (dd, *J* 7.5, 7.5 Hz, 3H, C(H)HCH₃), 1.30 (dddd, *J* 3.5, 13, 13, 13 Hz, 1H, H-4_{ax}), 1.55 (ddq, *J* 11.5, 13, 7.5 Hz, 1H, C(H)HCH₃), 1.60-1.75 (m, 2H, H-10a, C(H)HCH₃), 2.09 (dddd, *J* 1.5, 5, 13, 13 Hz, 1H, H-3_{ax}), 2.29 (s, 6H, NMe₂), 2.53 (m, *W*_{h/2} 24 Hz, 1H, H-4_{eq}), 2.60 (apparent t, *J* 5 Hz, 2H, OCH₂CH₂N), 2.63 (dd, *J* 4, 4, 11.5 Hz, 1H, H-1), 2.77 (dd, *J* 10, 16 Hz, 1H, H-9_{ax}), 2.88 (ddd, *J* 3, 11, 13 Hz, 1H, H-4a), 3.07 (dd, *J* 5, 16 Hz, 1H, H-9_{eq}), 3.75 (s, 3H, OMe), 3.92 (dm, *J* 13 Hz, *W*_{h/2} 8 Hz, 1H, H-3_{eq}), 3.97 (ddd, *J* 5, 10, 10 Hz, 1H, H-10), 4.13-4.26 (m, 2H, OCH₂CH₂N), 5.78 (d, *J* 1.5 Hz, 1H, vinyl-H), 6.58 (d, *J* 2.5 Hz, 1H, H-8), 6.72 (dd, *J* 2.5, 8.5 Hz, 1H, H-6), 7.17 (d, *J* 8.5 Hz, 1H, H-5), ¹³C n.m.r. (75.5 MHz, CDCl₃) See Table 2, *m/z* 175 (1), 171 (2), 163 (1), 145 (1), 135 (1), 72 (9), 71 (96), 59 (4), 58 (100).

2-(Dimethylamino)ethyl (Z)-(1R,4aS*,10S*,10aS*)-1-Ethyl-10-hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-ylideneacetate (15)*. The *Z* ethyl ester (9) (500 mg, 1.45 mmol) was converted to the dimethylaminoethyl ester by a method similar to that described for the preparation of the *E* analogue (10). Purification by radial chromatography (10% MeOH/CHCl₃) gave the ester (15) (390 mg, 69% over two steps) as a solid, m p 97-9°, Found. C, 71.31, H, 8.40, N, 3.56% C₂₃H₃₃NO₄ requires C, 71.29, H, 8.58, N, 3.61%, ¹H n.m.r. (300 MHz, CDCl₃) δ 0.85 (dd, *J* 7.5, 7.5 Hz, 3H, C(H)HCH₃), 1.33 (m, *W*_{h/2} 45 Hz, 1H, H-4_{ax}), 1.55 (ddq, *J* 11.5, 13, 7.5 Hz, 1H, C(H)HCH₃), 1.62 (ddd, *J* 4, 10, 11 Hz, 1H, H-10a), 1.75 (ddq, *J* 4, 13, 7.5 Hz, C(H)HCH₃), 2.22 (m, *W*_{h/2} 20 Hz, 1H, H-3_{eq}), 2.28 (s, 6H, NMe₂), 2.46-2.62 (m, 4H, H-3_{ax}, H-4_{eq}, OCH₂CH₂N), 2.75 (dd, *J* 10, 16 Hz, 1H, H-9_{ax}), 2.90 (br dd, *J*=11, 11 Hz, 1H, H-4a), 3.12 (dd, *J* 5, 16 Hz, 1H, H-9_{eq}), 3.75 (s, 3H, OMe), 3.95 (ddd, *J* 5, 10, 10 Hz, 1H, H-10), 4.12-4.25 (m, 2H, OCH₂CH₂N), 4.35 (ddd, *J* 4, 4, 11.5 Hz, 1H, H-1), 5.78 (d, *J* 1 Hz, 1H, vinyl-H), 6.59 (d, *J* 2.5 Hz, 1H, H-8), 6.71 (dd, *J* 2.5, 8.5 Hz, 1H, H-6), 7.14 (d, *J* 8.5 Hz, 1H, H-5), ¹³C n.m.r. (75.5 MHz, CDCl₃) See Table 2, *m/z* 171 (2), 163 (1), 73 (1), 72 (15), 71 (99), 59 (4), 58 (100).

Optical Resolution of Ethyl (E)-(4aR,10R*,10aR*)-10-Hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-ylideneacetate (4)*. Oxalyl chloride (750 μl, 8.6 mmol) was added dropwise to a solution of DMF (700 μl, 9.0 mmol) in CH₂Cl₂ (25 ml) at 0° under an atmosphere of Ar. After stirring for 5 min, (1S)-(-)

camphanic acid (1.54 g, 7.8 mmol) was added and the mixture was stirred for a further 5 min. A solution of the alcohol (4) (2.5 g, 7.9 mmol) in dry pyridine (5 ml) was then added dropwise; the mixture was allowed to warm to room temperature and was stirred for 1 hr. The reaction mixture was then diluted with CH_2Cl_2 , washed with cold dilute HCl, water, dried (MgSO_4) and the solvent was removed *in vacuo*. Radial chromatography (25% EtOAc/petrol) gave the mixture of diastereomeric camphanates (3.44 g, 88%) as a semi-solid. Fractional crystallisation from CH_2Cl_2 /petrol gave the (4*aS*,10*S*,10*aS*)-camphanate (18) (1.43 g, 36%) with 100% d e by h p l c analysis (5% EtOAc/petrol, 7.0 ml min^{-1} , R_f 20.8 mm), m.p. 187.5-8.5°, $[\alpha]_D^{20} = -20.0^\circ$ ($c = 1.15$, CHCl_3); Found: C, 69.97; H, 7.25%. $\text{C}_{29}\text{H}_{32}\text{O}_7$ requires C, 70.14; H, 7.31%, ^1H n.m.r. (300 MHz, CDCl_3): δ 1.02, 1.10, 1.15 (3 x s, each 3H, Me-4', 2 x Me-7'), 1.28 (t, J 7 Hz, 3H, OCH_2CH_3), 1.39 (dddd, J 3.5, 13, 13, 13 Hz, 1H, H-4_{ax}), 1.67-2.13 (m, 6H, H-1_{ax}, H-3_{ax}, H-10a, {H-5'}₂, H-6'_{endo}), 2.47 (ddd, J 4.5, 10.5, 13.5 Hz, 1H, H-6'_{exo}), 2.58-2.73 (m, 3H, H-1_{eq}, H-4_{eq}, H-4a), 2.88 (dd, J 10, 16 Hz, 1H, H-9_{ax}), 3.23 (dd, J 6, 16 Hz, 1H, H-9_{eq}), 3.77 (s, 3H, OMe), 4.08 (dm, J 14 Hz/ $W_{h/2}$ 7 Hz, 1H, H-3_{eq}), 4.15 (q, J 7 Hz, 2H, OCH_2CH_3), 5.15 (ddd, J 6, 10, 10 Hz, 1H, H-10), 5.72 (s, 1H, vinyl-H), 6.60 (d, J 2.5 Hz, 1H, H-8), 6.76 (dd, J 2.5, 8.5 Hz, 1H, H-6), 7.20 (d, J 8.5 Hz, 1H, H-5), ^{13}C n.m.r. (75.5 MHz, CDCl_3): δ 9.7 (Me-4'), 14.3 (OCH_2CH_3), 16.8, 16.9 (2 x Me-7'), 28.7* (C-6'), 28.9 (C-3), 30.8* (C-5'), 31.3 (C-4), 35.9 (C-1), 39.4 (C-9), 41.4 (C-4a), 45.9 (C-10a), 54.2, 54.8 (C-4', C-7'), 55.2 (OMe), 59.7 (OCH_2CH_3), 75.1 (C-10), 91.0 (C-1'), 112.7 (C-6), 113.6 (C-8), 115.0 (CHCO_2Et), 126.5 (C-5), 129.8 (C-4b), 134.5 (C-8a), 158.1 (C-7), 159.1 (C-2), 166.5 (CO_2Et), 167.3 (C-3'), 178.2 (OC(O)-1'), m/z : 299 (8), 298 (27), 269 (8), 225 (11), 224 (12), 211 (9), 210 (23), 185 (13), 172 (15), 171 (100)

(4*aR*,10*R*,10*aR*)-*O*-Methylmandelate (17) The mother liquor from the fractional crystallisation of the (4*aS*,10*S*,10*aS*)-camphanate (18) was concentrated *in vacuo* to give an oil (1.73 g), which by h p l c analysis had an 86% d e of the (4*aR*,10*R*,10*aR*)-camphanate (19) (R_f 24.0 mm) The oil was then dissolved in anhydrous ethanol (40 ml) with anhydrous K_2CO_3 (800 mg) and the mixture was heated under reflux for 2 hrs under an atmosphere of Ar The solution was then cooled, poured into water, and extracted with CH_2Cl_2 The extract was washed with water, dried (MgSO_4) and the solvent was removed *in vacuo* Radial chromatography (30% EtOAc/petrol) gave the optically enriched alcohol (760 mg, 2.4 mmol) as a solid. The alcohol was then esterified with (*R*)-(-)-*O*-methylmandelic acid (480 mg, 2.9 mmol) using oxalyl chloride/DMF, according to the procedure described for the preparation of the camphanate (18) Radial chromatography (30% EtOAc/petrol) gave the mixture of diastereomeric *O*-methylmandelates (1.06 g) as an oil H.p.l.c. analysis (5% EtOAc/petrol, 5.0 ml min^{-1}) indicated an 86% d e of the (4*aR*,10*R*,10*aR*)-*O*-methylmandelate (17) (R_f 13.1 mm, (4*aS*,10*S*,10*aS*)-*O*-methylmandelate (16), R_f 11.8 mm) Fractional crystallisation from ether/petrol gave the (4*aR*,10*R*,10*aR*)-*O*-methylmandelate (17) (870 mg, 24% from initial racemic alcohol (4)) with 100% d e by h p l c analysis, m.p. 120-1°, $[\alpha]_D^{20} = -15.0^\circ$ ($c = 1.36$, CHCl_3), Found: C, 72.28, H, 7.09% $\text{C}_{28}\text{H}_{32}\text{O}_6$ requires C, 72.39, H, 6.94%; ^1H n.m.r. (300 MHz, CDCl_3): δ 1.19-1.34 (m, 4H, H-4_{ax}, OCH_2CH_3), ca 1.60 (m, 1H, H-10), 1.65-1.75 (m, 2H, H-1_{ax}, H-1_{eq}), 1.90 (ddd, J 4, 13, 13 Hz, 1H, H-3_{ax}), 2.50-2.61 (m, 2H, H-4_{eq}, H-4a), 2.84 (dd, J 10, 16 Hz, 1H, H-9_{ax}), 3.21 (dd, J 6, 16 Hz, 1H, H-9_{eq}), 3.44 (s, 3H, C2'-OMe), 3.76 (s, 3H, OMe), 3.94 (dm, J 14 Hz/ $W_{h/2}$ 7 Hz, 1H, H-3_{eq}), 4.14 (q, J 7 Hz, 2H, OCH_2CH_3), 4.80 (s, 1H, H-2), 5.02 (ddd, J 6, 10, 10 Hz, 1H, H-10), 5.22 (s, 1H, vinyl-H), 6.57 (d, J 2.5 Hz, 1H, H-8), 6.73 (dd, J 2.5, 8.5 Hz, 1H, H-6), 7.13 (d, J 8.5 Hz, 1H, H-5), 7.38-7.51 (m, 5H, ArH"); ^{13}C n.m.r. (75.5 MHz, CDCl_3): δ 14.3 (OCH_2CH_3), 27.3 (C-3), 31.3 (C-4), 35.9 (C-1), 38.5 (C-9), 41.3 (C-4a), 46.2 (C-10a), 55.2 (OMe), 57.2 (2'-OMe), 59.6 (OCH_2CH_3), 73.9 (C-10), 82.5 (C-2'), 112.5 (C-6), 113.7 (C-8), 114.6 (CHCO_2Et), 126.4 (C-5), 127.4 (C-2'', C-6''), 128.8 (C-3'', C-5''), 129.0 (C-4''), 129.8 (C-4b), 134.7 (C-1''), 136.5 (C-8a), 158.0 (C-7), 159.4 (C-2), 166.6 (CO_2Et), 170.3 (C-1'), m/z 299 (9), 298 (43), 210 (10), 172 (8), 171 (44), 122 (10), 121 (100)

Ethyl (E)-(4*aS*,10*S*,10*aS*)-10-Hydroxy-7-methoxy-3,4,4*a*,9,10,10*a*-hexahydrophenanthren-2(1H)-ylideneacetate (+)-(4) The (4*aS*,10*S*,10*aS*)-camphanate (18) (1.00 g, 2.0 mmol) was converted to the alcohol (+)-(4) according to the procedure described for the preparation of the *O*-methylmandelate (17) Radial chromatography (30% EtOAc/petrol) gave the alcohol (+)-(4) (450 mg, 71%) which crystallised from CH_2Cl_2 /petrol, m.p. 89-90°, $[\alpha]_D^{20} = +8.2^\circ$ ($c = 0.975$, CHCl_3)

(4*aS*,10*S*,10*aS*)-*O*-Methylmandelate (16) Oxalyl chloride (27 μl , 0.31 mmol) was added dropwise to a solution of DMF (27 μl , 0.35 mmol) in CH_2Cl_2 (1 ml) at 0° under an atmosphere of Ar After stirring for 5 min, (1*R*)-(-)-*O*-methylmandelic acid (53 mg, 0.32 mmol) was added and the mixture was stirred for a further 5 min A solution of the alcohol (+)-(4) (20 mg, 0.06 mmol) in dry pyridine (200 μl) was then added dropwise, the mixture was allowed to warm to room temperature and was stirred for 1 hr A few drops of water were then added to the reaction and the mixture stirred at room temperature for 30 min The reaction mixture was then diluted with CH_2Cl_2 , washed with cold dilute HCl, sat NaHCO_3 , water, dried (MgSO_4) and the solvent was removed *in vacuo*. The crude product was then examined by ^1H n.m.r. spectroscopy, ^1H n.m.r. (300 MHz, CDCl_3): δ 1.29 (t, J 7 Hz, 3H, OCH_2CH_3), 1.35 (dddd, J 3.5, 13, 13, 13 Hz, 1H, H-4_{ax}), 1.71 (dddd, J 3.5, 10, 12, 12 Hz, 1H, H-10a), 1.95 (dd, J 12, 12 Hz, 1H, H-1_{ax}), 1.99 (br dd, $J=13, 13$ Hz, 1H, H-3_{ax}), 2.40

$W_{h/2}$ 6 Hz, 1H, H-1_{eq}), 2.55-2.67 (m, 2H, H-4_{eq}, H-4a), 2.65 (dd, J 10, 16 Hz, 1H, H-9_{ax}), 16 Hz, 1H, H-9_{eq}), 3.46 (s, 3H, C2'-OMe), 3.74 (s, 3H, OMe), 4.03 (dm, J 14 Hz/ $W_{h/2}$ 7 Hz, 16 (q, J 7 Hz, 2H, OCH₂CH₃), 4.83 (s, 1H, H-2'), 5.06 (ddd, J 6, 10, 10 Hz, 1H, H-10), 5.61 (t), 6.49 (d, J 2.5 Hz, 1H, H-8), 6.72 (dd, J 2.5, 8.5 Hz, 1H, H-6), 7.16 (d, J 8.5 Hz, 1H, H-m, 5H, ArH")

(4aR,10R,10aR)-10-Hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-ylidene-

The (4aR,10R,10aR)-*O*-methylmandelate (17) (750 mg, 1.6 mmol) was dissolved in anhydrous) with anhydrous K₂CO₃ (600 mg) and the mixture was stirred at 60° (bath) for 2.5 hrs under an Ar. The solution was cooled, poured into water, and extracted with CH₂Cl₂. The extract was water, dried (MgSO₄) and the solvent was removed *in vacuo*. Radial chromatography (30% gave the alcohol (-)-(4) (471 mg, 92%) which crystallised from CH₂Cl₂/petrol, m.p. 89-90°, [α]_D 54, CHCl₃)

ino)ethyl (E)-(4aS,10S,10aS)-10-Hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-

acetate (+)-(10) The (4aS, 10S, 10aS) ester (+)-(4) (180 mg, 0.57 mmol) was converted to the ethyl ester by a method similar to that described for the preparation of the (*E*) racemic analogue ion by radial chromatography (10% MeOH/CHCl₃) gave the ester (+)-(10) (130 mg, 64% over solid, m.p. 88-90°, [α]_D = +20.4° (c = 0.51, CHCl₃))

ino)ethyl (E)-(4aR,10R,10aR)-10-Hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-

acetate (-)-(10) The (4aR,10R,10aR) ester (-)-(4) (400 mg, 1.27 mmol) was converted to the ethyl ester by a method similar to that described for the preparation of the (*E*) racemic analogue ion by radial chromatography (10% MeOH/CHCl₃) gave the ester (-)-(4) (340mg, 75% over two d, m.p. 89-91°, [α]_D = -18.9° (c = 0.56, CHCl₃))

tion of Ethyl (E)-(1R,4aS*,10S*,10aS*)-1-Ethyl-10-hydroxy-7-methoxy-3,4,4a,9,10,10a-hexa-*

ren-2(1H)-ylideneacetate (8) The alcohol (8) (1.10 g, 3.2 mmol) was esterified with (*R*)-(-)-*O*- acid (630 mg, 3.8 mmol) using oxalyl chloride/DMF according to the procedure described for the the camphanate (18). Radial chromatography (10% EtOAc/petrol) separated the mixture of ric *O*-methylmandelates. The higher R_f isomer, the (1R,4aS,10S,10aS)-*O*-methylmandelate (20) , was obtained as a gum, which by h.p.l.c. analysis (5% EtOAc/petrol, 5.0 ml min⁻¹, R_f 7.2 min) de, [α]_D = -33.0° (c = 1.31, CHCl₃), Found. C, 73.24; H, 7.48%. C₃₀H₃₆O₆ requires C, %; ¹H n.m.r. (300 MHz, CDCl₃) δ 0.56 (dd, J 7.5, 7.5 Hz, 3H, C(H)HCH₃), 1.26 (ddq, J , 1H, C(H)HCH₃), 1.30 (apparent t, J 7 Hz, 3H, OCH₂CH₃), 1.32 (dddd, J 4, 13, 13, 13 Hz, 45 (ddd, J 11.5, 13, 7.5 Hz, 1H, C(H)HCH₃), 1.96 (ddd, J 4, 11, 11 Hz, 1H, H-10a), 2.05 , 13, 13 Hz, 1H, H-3_{ax}), 2.30 (ddd, J 3.5, 4, 11.5 Hz, 1H, H-1), 2.55 (m, $W_{h/2}$ 24 Hz, 1H, H- J 10, 16 Hz, 1H, H-9_{ax}), 2.91 (ddd, J 3, 11, 13 Hz, 1H, H-4a), 3.07 (dd, J 5, 16 Hz, 1H, H-3H, C2'-OMe), 3.73 (s, 3H, OMe), 3.92 (dm, J 13 Hz/ $W_{h/2}$ 8 Hz, 1H, H-3_{eq}), 4.11-4.21 (m, 3), 4.82 (s, 1H, H-2'), 5.20 (ddd, J 5, 10, 11 Hz, 1H, H-10), 5.66 (d, J 1.5 Hz, 1H, vinyl-H), Hz, 1H, H-8), 6.72 (dd, J 2.5, 8.5 Hz, 1H, H-6), 7.15 (d, J 8.5 Hz, 1H, H-5), 7.34-7.50 (m, C n.m.r. (75.5 MHz, CDCl₃) δ 11.7 (CH₂CH₃), 14.3 (OCH₂CH₃), 18.6 (CH₂CH₃), 24.3 (C-), 35.4 (C-4a), 35.9 (C-9), 47.3 (C-1), 48.7 (C-10a), 55.2 (OMe), 57.4 (2'-OMe), 59.6 70.9 (C-10), 82.9 (C-2'), 112.7 (C-6), 113.4 (C-8), 115.6 (CHCO₂Et), 126.8 (C-2", C-6"), 128.7 (C-3", C-5"), 128.8 (C-4"), 130.3 (C-4b), 134.3 (C-1"), 136.1 (C-8a), 157.9 (C-7), 56.5 (CO₂Et), 170.3 (C-1'), *m/z*. 326 (25), 283 (6), 253 (6), 172 (14), 171 (62), 147 (7), 122

4aR,10R,10aR)-O-methylmandelate (21) (716 mg, 46%), which by h.p.l.c. analysis (R_f 9.5

0% de, crystallised from CH₂Cl₂/petrol, m.p. 86-7°, [α]_D = -13.7° (c = 1.11, CHCl₃), Found 36% C₃₀H₃₆O₆ requires C, 73.15, H, 7.37%, ¹H n.m.r. (300 MHz, CDCl₃) δ 0.24 (dd, J H, C(H)HCH₃), 0.93 (ddq, J 3.5, 13, 7.5 Hz, 1H, C(H)HCH₃), 1.26 (dddd, J 4, 13, 13, 13), 1.30 (apparent t, J 7 Hz, 3H, OCH₂CH₃), 1.31 (ddq, J 11.5, 13, 7.5 Hz, 1H, C(H)HCH₃), 5.4, 11.5 Hz, 1H, H-1), 1.85 (ddd, J 4, 11, 11 Hz, 1H, H-10a), 1.95 (dddd, J 1.5, 5, 13, 13), 2.51 (m, $W_{h/2}$ 24 Hz, 1H, H-4_{eq}), 2.80 (dd, J 10, 16 Hz, 1H, H-9_{ax}), 2.87 (ddd, J 3, 11, 13), 3.26 (dd, J 5, 16 Hz, 1H, H-9_{eq}), 3.43 (s, 3H, C2'-OMe), 3.75 (s, 3H, OMe), 3.83 (dm, J 13 1H, H-3_{eq}), 4.07-4.23 (m, 2H, OCH₂CH₃), 4.78 (s, 1H, H-2'), 5.13 (ddd, J 5, 10, 11 Hz, 1H, , J 1.5 Hz, 1H, vinyl-H), 6.55 (d, J 2.5 Hz, 1H, H-8), 6.72 (dd, J 2.5, 8.5 Hz, 1H, H-6), 7.14 H, H-5), 7.36-7.50 (m, 5H, ArH"), ¹³C n.m.r. (75.5 MHz, CDCl₃) δ 11.1 (CH₂CH₃), 14.3 18.2 (CH₂CH₃), 24.2 (C-3), 32.7 (C-4), 35.3 (C-4a), 36.5 (C-9), 46.7 (C-1), 48.8 (C-10a), 7.2 (2'-OMe), 59.6 (OCH₂CH₃), 70.6 (C-10), 82.4 (C-2'), 112.7 (C-6), 113.5 (C-8), 115.3 27.0 (C-5), 127.3 (C-2"), 128.8 (C-3", C-5"), 129.0 (C-4"), 130.2 (C-4b), 134.3 (C-

1"), 136 4 (C-8a), 157 9 (C-7), 162 6 (C-2), 166 5 (CO₂Et), 170.0 (C-1'); *m/z*: 327 (5), 326 (21), 283 (5), 253 (5), 172 (13), 171 (56), 122 (8), 121 (100)

Ethyl (E)-(1R,4aS,10S,10aS)-1-Ethyl-10-hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-ylideneacetate (+)-(8) The (1R,4aS,10S,10aS)-*O*-methylmandelate (20) (730 mg, 1.48 mmol) was converted to the alcohol (+)-(8) by a method similar to that described for the preparation of (-)-(4). Purification by radial chromatography (30% EtOAc/petrol) gave the *alcohol (+)-(8)* (443 mg, 87%) which crystallised from CH₂Cl₂/petrol, m.p. 132-3°, [α]_D = +2.5° (c = 1.04, CHCl₃).

Ethyl (E)-(1S,4aR,10R,10aR)-1-Ethyl-10-hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-ylideneacetate (-)-(8) The (1S,4aR,10R,10aR)-*O*-methylmandelate (21) (715 mg, 1.45 mmol) was converted to the alcohol (-)-(8) by a method similar to that described for the preparation of (-)-(4). Purification by radial chromatography (30% EtOAc/petrol) gave the *alcohol (-)-(8)* (400 mg, 80%) which crystallised from CH₂Cl₂/petrol, m.p. 132-3°, [α]_D = -2.7° (c = 1.13, CHCl₃).

2-(Dimethylamino)ethyl (E)-(1R,4aS,10S,10aS)-1-Ethyl-10-hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-ylideneacetate (+)-(14) The (1R,4aS,10S,10aR) ester (+)-(8) (400 mg, 1.16 mmol) was converted to the dimethylaminoethyl ester (+)-(14) by a method similar to that described for the preparation of the analogue (10). Purification by radial chromatography (10% MeOH/CHCl₃) gave the *ester (+)-(14)* (412 mg, 92% over two steps) as a solid, m.p. 135-7°, [α]_D = +6.6° (c = 1.22, CHCl₃).

2-(Dimethylamino)ethyl (E)-(1S,4aR,10R,10aR)-1-Ethyl-10-hydroxy-7-methoxy-3,4,4a,9,10,10a-hexahydrophenanthren-2(1H)-ylideneacetate (-)-(14) The (1S,4aR,10R,10aS) ester (-)-(8) (400 mg, 1.16 mmol) was converted to the dimethylaminoethyl ester (-)-(14) by a method similar to that described for the preparation of the analogue (10). Purification by radial chromatography (10% MeOH/CHCl₃) gave the *ester (-)-(14)* (368 mg, 82% over two steps) as a solid, m.p. 135-7°, [α]_D = -6.3° (c = 1.21, CHCl₃).

Determination of Na⁺,K⁺-ATPase Inhibitory Activity

Na⁺,K⁺-ATPase activity was determined using pyruvate kinase and lactate dehydrogenase in a coupled enzyme assay.³¹ The assay medium consisted of 100 mM NaCl, 10 mM KCl, 3 mM MgCl₂, 0.1 mM EDTA, 50 mM imidazole (pH 7.5 at 30°C), 3 mM ATP, 4.5 mM phosphoenolpyruvate, 0.5 mM NADH, 2.5 U ml⁻¹ of pyruvate kinase, 2.5 U ml⁻¹ of lactate dehydrogenase and 0.01 U ml⁻¹ of ATPase in a total volume of 3 ml. The ATPase activity was measured at ambient temperature (30-35°C) by the decrease in absorption at 340 nm, using a Varian DMS-80 UV-Visible Spectrophotometer, in quartz cells with path length 1 cm.

Mono(cyclohexylammonium) phosphoenolpyruvate, disodium ATP, NADH and Na⁺,K⁺-ATPase were obtained from Sigma Chemical Co, USA. Pyruvate kinase and lactate dehydrogenase were obtained from Boehringer Mannheim, Australia. All other chemicals were of analytical grade. The Na⁺,K⁺-ATPase (product number A 7510) was the sodium iodide extracted fraction of Nakao *et al.*³² from porcine cerebral cortex and had a total activity of between 0.45-0.51 U mg⁻¹ protein, depending on the batch, of which 3-6% was ouabain insensitive.

Analogues (as their free bases) were introduced as dimethylsulphoxide solutions so that the concentration of the solvent was always 1% (v/v). Suitable controls established that the amount of dimethylsulphoxide added did not influence the assays, and that the analogues had no influence on the activities of pyruvate kinase or lactate dehydrogenase. The inhibitory activity of an analogue was usually determined by testing, in duplicate, four concentrations covering a 10-fold concentration range around the IC₅₀ value. For all analogues, at all concentrations covered, equilibrium inhibition was established immediately and preincubation was unnecessary. The IC₅₀ value was determined by interpolation (with the exception of analogues with IC₅₀ > 1 mM, which were determined by extrapolation) of a Hill plot of the form

$$\log \frac{\gamma}{100 - \gamma} = h \log [C] - \log IC_{50}$$

where γ is the percentage inhibition of ouabain sensitive activity at an analogue concentration [C].¹¹ For all analogues linear plots were obtained and the Hill coefficient *h* was equal to 1.0 ± 0.1

Acknowledgements We are grateful for financial assistance in the form of the Earnest and Evelyn Havill Shacklock Scholarship in Science (to R. W. B.) and from the Australian Research Grant Scheme, and to Dr. L. T. Byrne for assistance in the acquisition and interpretation of n.m.r. spectra.

References

- (1) Baker, R W., Knox, J.R. and Rogers, D H., *Tetrahedron*, preceding paper, this issue.
- (2) Wadsworth, W.S., Jr. and Emmons, W.A., *J Am Chem. Soc*, **1961**, *83*, 1733.
- (3) Shumoji, K., Taguchi, H., Oshima, K., Yamamoto, H. and Nozaki, H., *J Am Chem Soc*, **1974**, *96*, 1620.
- (4) Strekowski, L., Melean, V. and Battiste, M.A., *Tetrahedron Lett.*, **1984**, *25*, 5603.
- (5) Hauth, H., Stauffacher, D., Niklaus, P. and Melera, A., *Helv. Chim. Acta*, **1965**, *48*, 1087.
- (6) Stothers, J.B., *Carbon-13 NMR Spectroscopy*, Academic Press: New York, 1972, pp. 80-3.
- (7) Stothers, J.B., *Carbon-13 NMR Spectroscopy*, Academic Press: New York, 1972, pp. 65-7.
- (8) Saigo, K., Usui, M., Kazunori, K., Shimada, E. and Mukaiyama, T., *Bull Chem. Soc Jpn*, **1977**, *50*, 1863.
- (9) The structures (16) to (21), cassaine (22), digitoxigenin (23) and those prefixed by (+) or (-) represent the single enantiomer; all other structures represent racemic mixtures.
- (10) Trost, B M., Belletine, J.L., Godleski, S., McDougal, P.G., Balkovec, J.M., Baldwin, J.J., Christy, M.E., Ponticello, G.S., Vargu, S.L. and Springer, J.P., *J Org Chem*, **1986**, *51*, 2370.
- (11) Schönfeld, W., Weiland, J., Lindig, C., Masnyk, M., Kabat, M.M., Kurek, A., Wicha, J. and Repke, K R.H., *Naunyn-Schmiedeberg's Arch. Pharmacol*, **1985**, *329*, 414
- (12) Peters, T., Raben, R. and Wassermann, O., *Eur J Pharmacol*, **1974**, *26*, 166.
- (13) Tobin, T., Akera, T., Brody, S.L., Ku, D. and Brody, T.M., *Eur J Pharmacol*, **1975**, *32*, 133.
- (14) Fullerton, D S., Yoshioaka, K., Rohrer, D.C., From, A.H.L. and Ahmed, K., *Science*, **1979**, *205*, 917, Ahmed, K., Rohrer, D C., Fullerton, D.S., Deffo, T., Kitatsuji, E. and From, A.H.L., *J Biol. Chem.*, **1983**, *258*, 8092, Fullerton, D.S., Kitatsuji, E., Deffo, T., Rohrer, D C., Ahmed, K. and From, A.H.L. *Curr Top Membr Transp*, **1983**, *19*, 257; Rohrer, D C., Kihara, M., Deffo, T., Rathore, H., Ahmed K., From, A.H.L. and Fullerton, D.S., *J Am Chem Soc*, **1984**, *106*, 8269; From, A.H.L., Fullerton D.S., Deffo, T., Kitatsuji, E., Rohrer, D.C. and Ahmed, K., *J Mol Cell Cardiol.*, **1984**, *16*, 835, Fullerton, D S., Ahmed, K., From, A.H.L., McParland, R.H., Rohrer, D C. and Griffin, J.F., in *Molecular Graphics and Drug Design*, Burgen, A.S V., Roberts, G.C.K. and Tute, M.S., eds, Elsevier, Amsterdam, 1986, pp. 257-84
- (15) Repke, K.R.H., Schönfeld, W., Weiland, J., Megges, R. and Hache, A., in *Design of Enzyme Inhibitors as Drugs*, Sandler, M. and Smith, H.J., eds, Oxford University Press: New York, 1989, pp. 435-502.
- (16) Gelbart, A. and Thomas, R., *J Med Chem*, **1978**, *21*, 284.
- (17) La Bella, F.S., Bihler, I., Templeton, J., Kim, R S., Hnatowich, M. and Rohrer, D., *Federation Proc*, **1985**, *44*, 2806
- (18) Templeton, J.F., Sashi Kumar, V.P., Cote, D., Bose, D., Elliott, D., Kim, R S. and La Bella, F S, *J Med Chem*, **1987**, *30*, 1502.
- (19) Thomas, R., Brown, L., Boutagy, J. and Gelbart, A., *Circ Res*, Supp 1, **1980**, 46.
- (20) Akera, T., Fox, A.L. and Greeff, K., in *Handbook of Experimental Pharmacology*, Greeff, K., ed., Vol 56/1, Springer-Verlag, Berlin, Heidelberg, New York, 1981, pp. 459-86
- (21) Full geometry optimisation was carried out using AM1²² parameters implemented in the MOPAC²³ package. The initial structure was largely derived from the X-ray crystal structure of (21), with the optimised structure differing little from that determined for (21).
- (22) Dewar, M.J S., Zoebisch, E.G., Healy, E.F. and Stewart, J.J.P., *J Am Chem Soc*, **1985**, *107*, 3902
- (23) MOPAC Version 5.00, from the Quantum Chemistry Program Exchange
- (24) Although the s-cis,syn conformation of the side-chain is expected to be the minimum energy conformation the energy difference between it and an s-trans,syn conformation should not be so great as to exclude the possibility that the analogue may bind to Na⁺, K⁺-ATPase with an s-trans,syn side-chain conformation, see Montaudou, G., Librando, V., Cuccamese, S. and Maravigna, P., *J Am Chem Soc*, **1973**, *95*, 6365; Loncharich, R.J., Schwartz, T.R. and Houk, K.N., *J Am Chem Soc*, **1987**, *109*, 14
- (25) Karle, I.L. and Karle, J., *Acta Cryst*, **1969**, *B25*, 434.
- (26) Jackman, L.M. and Sternhell, S., *Applications of Nuclear Magnetic Resonance Spectroscopy in Organic Chemistry*, 2nd Ed., Pergamon Press Oxford, 1969, pp 289-92
- (27) Bredt, J., *Ber*, **1893**, *26*, 3047
- (28) Meyer, W.L., Capshaw, C.E., Johnson, J.H., Klusener, A.R., Lobo, A.P. and McCarty, R.N., *J Org Chem*, **1977**, *42*, 527
- (29) Lapworth, A. and Lenton, W.H., *J Chem Soc*, **1901**, 1284
- (30) Neilson, D.G. and Peters, D.A.V., *J Chem Soc*, **1962**, 1519
- (31) Barnett, R.E., *Biochemistry*, **1970**, *9*, 4644
- (32) Nakao, T., Tashima, Y., Nagano, K. and Nakao, M., *Biochem Biophys Res Comm*, **1965**, *19*, 755